What’s on the horizon of HIV prevention? Here are five clinical trials to pay attention to, if you’re interested in what the next big breakthrough in the HIV prevention field may be.
13 hours ago | BETA blog
Rectal microbicide gels, applied either daily or before and after sex, are currently being investigated as an option for HIV pre-exposure prophylaxis (PrEP). Given that many people who have anal lready use lube, one hope is for an HIV-prevention product that people could essentially use in place of a lube. But can gels provide enough coverage across rectal tissue if people don’t use an applicator?
18 March 2016 | BETA blog
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today that it would move forward with an open-label extension study of an HIV prevention tool for women: a silicone ring that continuously releases the experimental antiretroviral drug dapivirine in the vagina. The new study builds on recently announced findings from the ASPIRE trial which found that the dapivirine ring safely provided a modest level of protection against HIV infection in sub-Saharan African women.
14 March 2016 | National Institute of Allergy and Infectious Diseases
Analysis of BuzzFeed's coverage of vaginal ring studies.
01 March 2016 | Health News Review
This is the first time two phase-three clinical trials have confirmed statistically significant efficacy for a microbicide to prevent HIV. The dapivirine ring was designed to offer potentially long-acting protection against HIV through slow, continuous delivery of dapivirine into the vaginal tissues over the course of four weeks. But there are still several more steps that need to be followed before the ring becomes available to women.
01 March 2016 | The Conversation
The vaginal ring is one more addition to an already exciting array of antiretroviral-based biomedical options in the prevention toolbox that has ushered in a new era in HIV prevention.
26 February 2016 | International AIDS Society
Results from two large-scale studies of a vaginal ring that releases the antiretroviral medicine dapivirine to prevent HIV among women have shown protection of around 30% against HIV. The results are encouraging and show the urgent need to expand investment in research and development for female-controlled methods of HIV prevention. Although less effective than hoped for, the results are the first to show that a sustained release mechanism for antiretroviral medicine is feasible, safe and partially effective in preventing HIV infection among women. Follow-up studies are needed to build on these results and there is a need to better understand how to optimize the HIV prevention effect and support adherence.
24 February 2016 | UNAIDS
Kenneth Mayer: Despite our great progress, we require better tools to fight AIDS. That is why there is so much excitement around this year’s annual Conference on Retroviruses and Opportunistic Infections, which will convene in Boston Feb. 22-25. We are going to learn more about two emerging tools to control the HIV/AIDS epidemic: prevention medicines that are easy to use and protect those who are HIV negative from infection, and advances in vaccine research.
21 February 2016 | Boston Globe
Initiated and organised entirely by the community of people living with and at risk for HIV, the second European HIV Prevention Summit brought together representatives of civil society, the pharmaceutical industry, researchers and academia in Brussels between 29 and 31 January. In addition to a thorough examination of PrEP (pre-exposure prophylaxis), the summit discussed the latest developments in the research fields of vaccines, rectal and vaginal microbicides and antibodies and their utility in HIV prevention.
03 February 2016 | EATG
Non-specific or antiretroviral-based vaginal gels failed to work but new formulations offer hope.
11 January 2016 | IAVI Report